General Information about Amicus Therapeutics
Amicus Therapeutic is a biopharmaceutical company. This organization was founded in 2002 and it works to combat orphan and rare diseases. Amicus was founded by different venture capital firms who combined their resources. These firms include Radius Ventures, Canaan Partners and New Enterprise Associates. The company is led by three key people which include CEO John Crowley, COO Bradley Campbell and the company’s Chief Financial Officer, Willian Baird.
Amicus Therapeutics is a leading research and treatment facility in the fight against rare diseases. An orphan disease is a condition that is experienced by 200,000 people or fewer within a large population of people. A rare disease is defined by its ability to affect a small percentage of a population. Most rare diseases are genetic and the same is also true for orphan diseases.
The founders of Amicus realize that rare diseases can still negatively impact various ethnic groups and populations from around the world. Diseases such as cystic fibrosis, Lou Gehrig’s disease, Hamburger disease and Tourette’s syndrome falls into the rare and orphan diseases categories. Other diseases such as gigantism and job syndrome are also treated by this medical organization.
Various pharmaceutical treatment options consist of the Chaperone-Advanced Replacement Therapy or CHART. This is a proven enzyme replacement therapy that the founders use to treat people. CHART is the company’s leading treatment drug. It is used for various patients with unique conditions. This company has been helping the medical community to find viable solutions with their efforts in eliminating specific diseases.
Amicus Therapeutics opened up another facility in San Diego, California in 2008. Their original location is in Cranbury, New Jersey. This organization has also acquired Callidus Biopharma and Scioderm. These acquisitions helped Amicus Therapeutics expand its research and treatment options to combat unusual diseases such as Pompe. Amicus Therapeutics brings in a revenue of $18 million per year and is growing in a positive direction.